UT-MD Anderson Cancer Center: ASCO - New Antibody-drug Conjugate Shows Promising Safety and Response Rates for Patients With Rare Blood Cancer
June 03, 2025
June 03, 2025
HOUSTON, Texas, June 3 -- The University of Texas MD Anderson Cancer Center issued the following news release:
* * *
ASCO: New antibody-drug conjugate shows promising safety and response rates for patients with rare blood cancer
* Blastic plasmacytoid dendric cell neoplasm (BPDCN) is a rare, aggressive blood cancer that often involves the bone marrow, skin and, sometimes, lymph nodes.
* First-in-class antibody-drug conjugate, pivekimab sunirine . . .
* * *
ASCO: New antibody-drug conjugate shows promising safety and response rates for patients with rare blood cancer
* Blastic plasmacytoid dendric cell neoplasm (BPDCN) is a rare, aggressive blood cancer that often involves the bone marrow, skin and, sometimes, lymph nodes.
* First-in-class antibody-drug conjugate, pivekimab sunirine . . .